Table 2 Technical details of method for CXCL12 quantification
From: A meta-analysis of CXCL12 expression for cancer prognosis
First autho r | Sample | Quantification method | Other factors analysed | Antigen retrieval method | Sample storage | Antibody/ELISA source (CAT number) | Definition of expression level cutoffs | Follow-up collection | Outcome measures |
|---|---|---|---|---|---|---|---|---|---|
Tumour tissue | IHC | CXCR7 | Autoclave+citrate | FFPE | R&D Systems, Minneapolis, MN, USA | Arbitrary | Retrospective | OS | |
Guo cohort 26) (Guo et al, 2016) | Tumour tissue | IHC | CXCR7 | Autoclave+citrate | FFPE | R&D Systems | Arbitrary | Retrospective | OS |
Tumour tissue | IHC | CXCR4 | Target retrieval solution (Dako, Santa Clara, CA, USA) | FFPE | R&D Systems (MAB350) | Arbitrary | Retrospective | RFS | |
Tumour tissue | IHC | CXCR4 | Target retrieval solution (Dako) | FFPE | R&D Systems (MAB350) | Arbitrary | Prospective | RFS | |
Stanisavljević cohort 2 (Stanisavljević et al, 2016) | Tumour tissue | IHC | CXCR4 | Target retrieval solution (Dako) | FFPE | R&D Systems (MAB350) | Arbitrary | Prospective | RFS |
Serum | Protein array | Multiple (>10) | N/A | Frozen | Bio-Rad Laboratories (Hercules, CA, USA) (Bio-Plex 220 assay) | Data distribution | Retrospective | OS | |
Tumour tissue | IHC | HIF1a, CXCR4, VEGF | ? | FFPE | R&D Systems | Arbitrary | Prospective | OS | |
Tumour tissue | IHC | CXCR4, pCXCR4 | ? | FFPE | Abcam (Cambridge, UK) | ROC curve analysis | Retrospective | OS | |
Tumour tissue | IHC | CXCR4 | ? | FFPE | R&D SystemsAF-310-NA | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | CXCR4 | ? | FFPE | Abcam | Arbitrary | Retrospective | CSS | |
Tumour tissue | IHC | CXCR4 | Heat (100 °C, 60 min) | FFPE | R&D Systems | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | Multiple (>10) | ? | FFPE | ? | Arbitrary | Prospective | OS | |
Tumour tissue | IHC | CXCR4 | Citrate (pH 6.0, 100 °C, 15 min) | FFPE | R&D Systems (MAB350) | Arbitrary | ? | OS | |
Serum | ELISA | Multiple (>10) | n/a | Frozen | Assay Gate (Ijamsville, MD, USA) | ROC curve analysis | Prospective | OS, RFS | |
Tumour tissue | IHC | N/A | ? | FFPE | ? | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | CXCR4 | Citrate (pH 9.0, microwave 2–5 min) | FFPE | R&D Systems (?) | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | CEA, CA19-9, HGF | ? | FFPE | Biovision (Milpitas, CA, USA) (?) | ? | Prospective | OS, RFS | |
Tumour tissue | IHC | N/A | ? | FFPE | R&D Systems (MAB350) | ROC curve analysis | Retrospective | OS | |
Serum | ELISA | VEGF, PDGF, osteopontin, CEA | N/A | Frozen | Bio-Rad Laboratories (Bio-Plex 220 assay) | ROC curve analysis | Prospective | OS, RFS | |
Tumour tissue | IHC | CXCR4, CXCR7 | ? | FFPE | R&D Systems (MAB350) | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | CXCR4, CXCR7 | Epitope Retrieval Solution (Dako) | FFPE | Abcam (AB9797) | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | VEGF, MMP9 | 0.1% zymine (37 °C, 30 min) | FFPE | R&D Systems (?) | Arbitrary | ? | RFS | |
Tumour tissue | IHC | CXCR4, CXCR7 | Citrate (pH 6.0, 100 °C, 10 min) | FFPE | R&D Systems (MAB350) | ROC curve analysis | Retrospective | OS, RFS | |
Tumour tissue | IHC | N/A | Target Retrieval Solution (DAKO) | FFPE | R&D Systems (MAB350) | ROC curve analysis | Retrospective | CSS | |
Tumour tissue | IHC | N/A | Citrate (pH 6.0, microwave, 12 min) | FFPE | R&D Systems (MAB350) | ? | Retrospective | RFS | |
Tumour tissue | IHC | CXCR4 | EDTA (pH 9.0, microwave, 10 min) | FFPE | R&D Systems (MAB350) | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | CXCR4, CD133 | ? | FFPE | R&D Systems (MAB350) | Arbitrary | Retrospective | OS, RFS | |
Tumour tissue | IHC | N/A | Citrate (pH 6.0, microwave) | FFPE | Abcam (AB10395) | Arbitrary | Prospective | OS, RFS | |
Tumour tissue | IHC | FoxP3 | Tris/EDTA (pH 9.0, microwave) | FFPE | R&D Systems (MAB350) | Arbitrary | retrospective | CSS | |
Tumour tissue | IHC | CXCR4 | 0.5% Tween-20 in PBS | FFPE | R&D Systems (MAB350) | Arbitrary | ? | OS, RFS | |
Tumour tissue | IHC | N/A | EDTA (pH 9.0, 100 °C, 20 min) | FFPE | R&D Systems (?) | ROC curve analysis | prospective | OS, RFS | |
Tumour tissue | IHC | CXCR4 | ? | FFPE | Dianova (Hamburg, Germany) (?) | ROC curve analysis | ? | OS, RFS | |
Tumour tissue | IHC | N/A | Citrate (pH 6.0, 121 °C, 10 min) | FFPE | R&D Systems (?) | Arbitrary | Prospective | OS, RFS | |
Tumour tissue | IHC | CXCR4 | ? | FFPE | R&D Systems (MAB350) | Arbitrary | ? | OS | |
Tumour tissue | IHC | CXCR4 | ? | FFPE | R&D Systems (MAB350) | Arbitrary | Retrospective | RFS | |
Tumour tissue | IHC | CXCR4 | Citrate buffer (120 °C, 10 min) | FFPE | R&D Systems (MAB350) | Arbitrary | Retrospective | OS | |
Tumour tissue | IHC | N/A | ? | FFPE | R&D Systems (MAB172) | ? | ? | OS | |
Tumour tissue | IHC | CXCR4 | ? | FFPE | R&D Systems (MAB350) | ? | ? | OS |
